New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
08:31 EDTIPXLImpax reports FDA re-inspected its manufacturing facility in California
Impax Laboratories announced that the FDA performed a re-inspection of the Company's Hayward, California manufacturing facility from June 16 to July 31. At the conclusion of the inspection, the FDA issued a Form 483 with seven inspectional observations, two of which are designated as repeat observations. The FDA did not provide any status or classification to these observations and, pursuant to its established regulatory process, will defer classification until it has reviewed the Company's response to the inspection.
News For IPXL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 29, 2015
10:00 EDTIPXLOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:17 EDTIPXLImpax initiated with a Neutral at Nomura
Subscribe for More Information
September 25, 2015
09:16 EDTIPXLImpax receives positive CHMP opinion for NUMIENT
Subscribe for More Information
September 24, 2015
07:12 EDTIPXLImpax added to short-term buy list at Deutsche Bank
Subscribe for More Information
September 22, 2015
07:01 EDTIPXLImpax's generic version of Testred Capsules 10 mg. approved by FDA
Subscribe for More Information
06:19 EDTIPXLClinton to roll out plan to rein in prescription drug costs, USA Today reports
Subscribe for More Information
September 21, 2015
14:04 EDTIPXLClinton vow to end drug price gouging sinks biotechs
Biotech stocks have declined across the board in afternoon trading following a tweet by Presidential candidate Hillary Clinton criticizing the "outrageous" prices of specialty drugs. TURING STEPS UP PRICING: Clinton's tweet directly referenced Turing Pharmaceuticals' Daraprim treatment for toxoplasmosis, which recently had its price hiked from just $13.50 per pill to $750 after the privately-held company acquired the drug from Impax Laboratories (IPXL). Importantly, Daraprim was first approved by the FDA in 1953 and its patents have long since expired. No generic versions of the drug currently exist, perhaps in part due to Turing executive chairman Martin Shkreli's strategy of tightly controlling distribution, according to a New York Post article on the issue. In a Bloomberg TV interview this morning, Shkreli claimed that the drug remains underpriced compared to what he called its peers in the rare disease space. However, note that a World Health Organization analysis from 2013 reported that over 190,000 cases of toxoplasmosis occur globally every year and Daraprim continues to be listed on the organization's list of essential medicines for a basic health-care system. INDUSTRY CRITICISM: Turing's Daraprim pricing prompted a response from the Infectious Diseases Society of America and the HIV Medicine Association, which criticized the "unjustifiable" new cost of the drug and urged a "rational" pricing strategy. The news surrounding Daraprim also comes on the heels of Presidential candidate Bernie Sanders issuing a letter in August to Valeant (VRX) and Hospira (HSP), in which he requested information on the "enormous" price increases of two drugs Valeant acquired earlier in the year. REPUBLICAN CONGRESS: In a research note released this afternoon, RBC Capital analyst Michael Yee reminded investors that Republicans still control Congress, offering a sobering reminder that campaign trail promises often fall by the wayside once the candidate steps into office. Yee explained that, though drug pricing debates during next year's election will probably generate headline risk for the biotech space, the Republican-controlled Congress is unlikely to sign into law any material changes on the issue. BIOTECH STOCK ACTION: Hillary Clinton's promise to "lay out a plan" tomorrow to tackle "price gouging" in the specialty drug market sent numerous biotech stocks plunging. Aerie Pharmaceuticals (AERI) has crashed 12.6% at time of writing, while Retrophin (RTRX), Ultragenyx (RARE), and PTC Therapeutics (PTCT) are down 14.7%, 13.4%, and 11%, respectively. Biotech giants AbbVie (ABBV), Gilead (GILD), Bristol-Myers Squibb (BMY) and Biogen (BIIB) have also slipped in intraday trading, while the NASDAQ Biotechnology index is down roughly 4%.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use